No. Preimplantation genetic testing for aneuploidy, or PGT-A, screens cells sampled from an embryo for specified chromosome-copy findings. It answers one particular question. It does not test for all disease, it does not eliminate miscarriage, and it does not guarantee that a transfer will implant or that a pregnancy will end in a live birth.

That is not an argument against using it. It is an argument for being precise about what you are buying.

What PGT-A actually looks at

The biopsy samples trophectoderm cells, the outer layer that goes on to form the placenta rather than the fetus itself. The result describes chromosome copy number in those sampled cells. It does not screen for single-gene conditions unless separate testing is ordered, it does not detect structural differences, and it cannot see everything that shapes a child's health.

Results are also not always binary. Mosaic findings, where sampled cells show a mix, are common enough that every program needs a stated policy for them. Ask what your clinic does with a mosaic result before you have one, and ask who provides the genetic counseling that follows.

Where the real decisions sit

PGT-A may help answer particular clinical questions, and whether it helps yours depends on the case. This is a physician conversation, not a website conclusion. Discuss:

• the age of the egg source, which drives the expected proportion of euploid embryos
• how many embryos you are likely to have, since testing a small cohort changes the calculus
• the clinic's mosaic-result policy and its counseling pathway
• the biopsy and laboratory experience of the specific program doing the work
• cost, including biopsy, per-embryo testing and any additional freeze and thaw
• what, concretely, a result would change about your plan

That last question is the one worth sitting with. If a result would not change which embryo is transferred or when, the test is buying information rather than a decision.

The claims to refuse

Treating PGT-A as a guarantee is a recognized failure mode, and it appears in marketing more often than in clinical conversation. No one should tell you that a euploid result means a healthy baby, that it removes miscarriage risk, or that it makes prenatal testing unnecessary. Prenatal screening and diagnostic testing may still be offered during the pregnancy, and that is ordinary rather than a sign that something went wrong.

Be equally careful with success rates built on tested embryos. A live-birth rate per euploid transfer looks impressive precisely because it excludes embryos that did not survive testing. Ask for outcomes per retrieval and cumulative outcomes per patient alongside it. Denominators do most of the work in these numbers, and small clinic volumes make percentages unstable.

For two-father and single-father families

Donor-egg cycles usually involve a young egg source, which changes the expected aneuploidy picture compared with the general IVF population. If you are creating embryos with both fathers from one donor cohort, testing decisions interact with allocation decisions. A modest cohort split two ways produces two small cohorts, and small numbers make every individual result feel larger than it is. Discuss the split and the testing plan in the same conversation rather than in sequence, and do not expect equal egg allocation or equal embryo yield to be promised.

Professional guidance also strongly favors single embryo transfer in gestational-carrier cycles. A euploid result is not a reason to transfer two. The health risks of a multiple pregnancy fall on the gestational carrier and on the babies, and those risks do not shrink because an embryo tested well.

The honest summary

PGT-A is a screening tool with a defined scope, real utility in some cases, and no ability to promise an outcome. Ask what it tests, what it misses, what a mosaic result triggers, and what a result would change. Then decide with your clinical team. If you want help framing the question before that appointment, get in touch.